Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE versus VELOSEF 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE versus VELOSEF 500.
CEFEPIME HYDROCHLORIDE vs VELOSEF '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase and carboxypeptidase activity, leading to cell lysis.
Cephradine inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis and death. It is a first-generation cephalosporin with bactericidal activity.
1-2 g IV every 8-12 hours; for uncomplicated urinary tract infections, 500 mg IV every 12 hours.
500 mg orally every 6 hours for 10 days.
None Documented
None Documented
2-2.3 hours in healthy adults (prolonged to 13-15 hours in severe renal impairment; requires dosage adjustment).
Terminal elimination half-life: 1.2 hours in adults with normal renal function; prolonged to 8-15 hours in severe renal impairment (CrCl <10 mL/min); clinical context: dosing interval adjustment required for renal impairment
Primarily renal (≈85% unchanged via glomerular filtration and tubular secretion); biliary/fecal <1%.
Renal excretion of unchanged drug: >90% (glomerular filtration and tubular secretion); biliary/fecal: <1%
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic